Youle M S, Hawkins D A, Lawrence A G, Tenant-Flowers M, Shanson D C, Gazzard B G
Department of Genito-Urinary Medicine, St. Stephen's Hospital, London, U.K.
J Acquir Immune Defic Syndr (1988). 1989;2(1):59-62.
Fusidic acid has previously been noted to prevent syncytial formation by human immunodeficiency virus (HIV) in vitro. Since this drug is a cheap, usually well-tolerated substance with known toxicity profile, an open, uncontrolled trial was undertaken to evaluate its possible efficacy in HIV disease. Twenty HIV antibody positive patients (10 with AIDS and 10 with ARC) were treated with sodium fusidate 500 mg every 8 h for up to 3 months. One patient died during therapy and six ceased treatment due to adverse events. Rash, nausea, diarrhea, and/or abdominal pain caused difficulties in all patients. There was no significant improvement in clinical state or T-helper cell levels, and no observed decrease in HIV p24 antigen during treatment. We conclude that in this open trial, sodium fusidate had no observable beneficial clinical, virological, or immunological effects.
以前有研究指出，夫西地酸在体外可阻止人类免疫缺陷病毒（HIV）形成合胞体。鉴于这种药物价格低廉，通常耐受性良好且毒性特征已知，因此开展了一项开放、非对照试验，以评估其对HIV疾病的潜在疗效。20名HIV抗体阳性患者（10例艾滋病患者和10例艾滋病相关综合征患者）接受了夫西地酸钠治疗，每8小时服用500毫克，最长治疗3个月。1例患者在治疗期间死亡，6例因不良事件停止治疗。皮疹、恶心、腹泻和/或腹痛给所有患者带来了困扰。临床状态或辅助性T细胞水平没有明显改善，治疗期间也未观察到HIV p24抗原减少。我们得出结论，在这项开放试验中，夫西地酸钠没有可观察到的有益临床、病毒学或免疫学效果。
